351 subjects with moderate psoriasis were randomized to DFD-01 (n=174), Diprolene (n=90), or Vehicle (n=87). Mean BSA was 13-14%. Treatment success was achieved in % DFD-01, % Diprolene, and % Vehicle (P< DFD-01 vs Vehicle) at day 15. Treatment success at day 8 was 10% DFD-01, % Diprolene, and % Vehicle (P= DFD-01 vs Vehicle). TSS was significantly reduced with DFD-01 compared with Vehicle at days 4, 8, and 15 (P ≤ ) and compared with Diprolene at day 4 (P=). DFD-01 relieved signs of erythema and scaling earlier than Diprolene or Vehicle, showing significant improvements on day 4 (P ≤ ). All products were well tolerated. Significantly more burning/stinging was reported with Diprolene than DFD-01 (% vs %, P=).
Jul 31, 2017, 06:00 ET